Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.

Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE.

J Neurooncol. 2019 Aug 9. doi: 10.1007/s11060-019-03258-0. [Epub ahead of print]


Deconstructing Lipid Kinase Inhibitors by Chemical Proteomics.

McCloud RL, Franks CE, Campbell ST, Purow BW, Harris TE, Hsu KL.

Biochemistry. 2018 Jan 16;57(2):231-236. doi: 10.1021/acs.biochem.7b00962. Epub 2017 Nov 22.


The Ligand Binding Landscape of Diacylglycerol Kinases.

Franks CE, Campbell ST, Purow BW, Harris TE, Hsu KL.

Cell Chem Biol. 2017 Jul 20;24(7):870-880.e5. doi: 10.1016/j.chembiol.2017.06.007. Epub 2017 Jul 14.


Dual activities of ritanserin and R59022 as DGKα inhibitors and serotonin receptor antagonists.

Boroda S, Niccum M, Raje V, Purow BW, Harris TE.

Biochem Pharmacol. 2017 Jan 1;123:29-39. doi: 10.1016/j.bcp.2016.10.011. Epub 2016 Oct 28.


Interstitial flow differentially increases patient-derived glioblastoma stem cell invasion via CXCR4, CXCL12, and CD44-mediated mechanisms.

Kingsmore KM, Logsdon DK, Floyd DH, Peirce SM, Purow BW, Munson JM.

Integr Biol (Camb). 2016 Dec 5;8(12):1246-1260.


A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.

Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY.

Clin Cancer Res. 2015 Aug 15;21(16):3610-8. doi: 10.1158/1078-0432.CCR-14-3220. Epub 2015 Apr 24.


Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia.

Clarke RH, Moosa S, Anzivino M, Wang Y, Floyd DH, Purow BW, Lee KS.

PLoS One. 2014 Oct 28;9(10):e111199. doi: 10.1371/journal.pone.0111199. eCollection 2014.


Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim.

Floyd DH, Zhang Y, Dey BK, Kefas B, Breit H, Marks K, Dutta A, Herold-Mende C, Synowitz M, Glass R, Abounader R, Purow BW.

PLoS One. 2014 May 7;9(5):e96239. doi: 10.1371/journal.pone.0096239. eCollection 2014.


Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers.

Dominguez CL, Floyd DH, Xiao A, Mullins GR, Kefas BA, Xin W, Yacur MN, Abounader R, Lee JK, Wilson GM, Harris TE, Purow BW.

Cancer Discov. 2013 Jul;3(7):782-97. doi: 10.1158/2159-8290.CD-12-0215. Epub 2013 Apr 4.


A novel fixative for immunofluorescence staining of CD133-positive glioblastoma stem cells.

Sherman JH, Redpath GT, Redick JA, Purow BW, Laws ER, Jane JA Jr, Shaffrey ME, Hussaini IM.

J Neurosci Methods. 2011 May 15;198(1):99-102. doi: 10.1016/j.jneumeth.2011.03.003. Epub 2011 Mar 23.


Glioblastoma genetics: in rapid flux.

Purow BW, Schiff D.

Discov Med. 2010 Feb;9(45):125-31. Review.


Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.

Schiff D, Purow BW.

Nat Rev Neurol. 2009 Jun;5(6):303-4. doi: 10.1038/nrneurol.2009.57.


Notch-1 regulates transcription of the epidermal growth factor receptor through p53.

Purow BW, Sundaresan TK, Burdick MJ, Kefas BA, Comeau LD, Hawkinson MP, Su Q, Kotliarov Y, Lee J, Zhang W, Fine HA.

Carcinogenesis. 2008 May;29(5):918-25. doi: 10.1093/carcin/bgn079. Epub 2008 Mar 20.


Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA.

Cancer Cell. 2006 May;9(5):391-403.


Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation.

Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, Maric D, Eberhart CG, Fine HA.

Cancer Res. 2005 Mar 15;65(6):2353-63.


Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.

Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB.

J Clin Oncol. 2003 Jun 15;21(12):2299-304.


Supplemental Content

Loading ...
Support Center